Status:
ACTIVE_NOT_RECRUITING
A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
Lead Sponsor:
Bernie Eigl
Collaborating Sponsors:
Vancouver Prostate Centre
Lady Davis Institute
Conditions:
Metastatic Bladder Cancer
Metastatic Urothelial Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors. Currently, doc...
Detailed Description
Recently, the first targeted therapy for patients with metastatic urothelial cancer (mUC) received approval, i.e. erdafitinib. Erdafitinib is a pan-FGFR small molecule inhibitor. Approximately twenty ...
Eligibility Criteria
Inclusion
- Patients with metastatic bladder cancer who are about to undergo tissue testing for FGFR mutations and who have blood samples drawn during the management of their disease are eligible to be included in this analysis.
Exclusion
- Metastatic bladder cancer patients who will not have tissue sent for FGFR testing will be excluded from this study.
Key Trial Info
Start Date :
January 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT06129084
Start Date
January 11 2021
End Date
December 31 2026
Last Update
December 15 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Arthur J.E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada, T2N 5G2
2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
3
BC Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
4
London Health Sciences Centre
London, Ontario, Canada, N6A 5W9